

Prof. Dr. med. Bastian Schilling

Erhard F, Dölken L, Schilling B, Schlosser A. (2020). Identification of the cryptic HLA-I immunopeptidome. *Cancer Immunol Res*, accepted for publication

Liu D**, Schilling B**, Liu D, Sucker A, Livingstone E, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis C, He MX, Elmarkaby H, Dietlein F, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberger R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Garraway L, Regev A, Flaherty K, Paschen A, van Allen EM*, Schadendorf D* (2019). Integrative molecular and clinical modeling of clinical outcomes to PD-1 blockade in metastatic melanoma patients. *Nat Med*. Dec;25(12):1916-1927. **equally contributing first authors, *corresponding authors

Van Allen EM**, Miao D**, Schilling B**, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D*, Garraway LA* (2015). Genomic correlates of response to CTLA4 blockade in metastatic melanoma. *Science* 350(6257):207-11. **equally contributing first authors, *corresponding authors

Schilling B**, Sondermann W, Zhao F, Griewank K, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U*, Schadendorf D*(2014). Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. *Ann Oncol* 25(3):747-53. **corresponding author, *equally contributing senior authors

Schilling B**, Sucker A, Griewank K, Zhao F, Weide B, Görgens A, Giebel B, Schadendorf D, Paschen A (2013). Vemurafenib reverses immunosuppression by myeloid-derived suppressor cells. *Int J Cancer* 133(7):1653-63. **corresponding author